Gabriel NicolasContreras Martin United StatesUniversity of Miami Miller School of Medicine

Gabriel NicolasContreras Martin
I, Gabriel Contreras, MD, MPH, earned my medical degree in 1984 from the Autonomous University of Guadalajara in Mexico. I trained in Internal medicine, nephrology, hypertension, critical care, and earned a degree as Master in Public Health between 1989 and 2003. In 1996, I joined the School of Medicine at the University of Miami. During my time as faculty in the Department of Medicine, I have been involved in the development and establishment of a successful clinical research program in the Division of Nephrology. I have an ongoing commitment to improving kidney disease outcomes among racial and ethnic minorities throughout the clinical research program at the University of Miami, Miller School of Medicine.
Institution

Day 1 - Sunday April 14, 2024

Time Session
9 a.m.
10:30 a.m.
Precise Phenotyping and Treatment
SK01
HeatherReich Chairperson CanadaUniversity of Toronto, University Health Network
SebastiánJaurretche Chairperson sebastianjaurretche@hotmail.comArgentinaSanatorio Parque SA
  • Deciphering the IGAN Cell Atlas
    JulioSaez-Rodriguez Speaker julio.saez@uni-heidelberg.deGermanyHeidelberg University
  • Complement-mediated Kidney Diseases in the Era of Complement Inhibitors
    MarinaVivarelli Speaker marina.vivarelli@opbg.netItalyLaboratory of Nephrology, Bambino Gesù Children's Hospital
  • CART-T
    JonathanHogan Speaker jonathan.hogan@cabalettabio.comCabaletta Bio
  • New Targets to Reduce the Burden of Rare Kidney Diseases
    LauraMariani Speaker lmariani@umich.eduUnited StatesUniversity of Michigan
  • Q and A
Hall C4
11 a.m.
12 p.m.
Plenary Session 2: CrisprCas9 Therapy for Sickle Cell Diseases: How Do We Go from Discovery to Equitable Availability of Gene Therapy for All? (Obiageli Eunice Nnodu, Nigeria)
PL2
AgnesFogo Chairperson United States
GuillermoRosa Diez Chairperson guillermo.rosadiez@hospitalitaliano.org.arArgentinaHospital Italiano de Buenos Aires; Argentinean Society of Nephrology; Latinoamerican Society of Nephrology and Hypertension; International Society of Nephrology
  • My Story
    VictoriaGray Speaker vwright_03@yahoo.comUnited States
  • CrisprCas9 Therapy for Sickle Cell Diseases: How Do We Go from Discovery to Equitable Availability of Gene Therapy for All? Hugh de Wardener Lecture
    Obiageli EuniceNnodu Speaker oennodu@gmail.comNigeriaUniversity of Abuja
Hall A

Day 2 - Monday April 15, 2024

Time Session
9 a.m.
10:30 a.m.
Insights From Understanding Heterogeneous Trajectories to Kidney Failure
LF03
FacundoDaminato Chairperson fmdaminato@hotmail.comArgentina
Magdalena Madero Chairperson MexicoChief of Nephrology, Instituto Nacional de Cardiol
PietroRavani Chairperson pravani@ucalgary.caCanadaUniversity of Calgary
  • Non-neoplastic Lesions in Nephrectomy Samples: Implications for Kidney Function
    JairMunoz Mendoza Speaker JMMendoza@med.miami.eduUnited StatesUniversity of Miami
  • Understanding the Heterogeneous Trajectory of CKD
    MorganGrams Speaker morgan.grams@nyulangone.orgUnited StatesNew York University
  • Review of Medical Therapies Proven to Delay CKD Progression
    DoreenZhu Speaker doreen.zhu@ndph.ox.ac.ukUnited KingdomUniversity of Oxford
  • Impact of Obesity and Novel Treatment Strategies on CKD Progression
    PeterRossing Speaker DenmarkSteno Diabetes Center Copenhagen
  • Q and A
Hall C4
Hypertension - the Cutting Edge: Advances in Science and Management
IK03
TaraChang Chairperson tichang@stanford.eduUnited StatesStanford University
Veronica Ferraris Chairperson veronica.ferraris@hospitalitaliano.org.arServicio de Nefrología Pediátrica. Hospital Italiano de Buenos Aires. (Argentina)
  • Behind the Numbers: Exploring the Molecular Mechanisms of Hypertension
    GerardoGamba Speaker gamba@biomedicas.unam.mxMexicoUniversidad Nacional Autónoma de México
  • Hypertension - the Cutting Edge: Is It Time for Sex-specific Management of Hypertension?
    TaliElfassy Speaker t.elfassy@med.miami.eduUnited States
  • State-of-the-Art Treatment of Hypertension in Pediatrics With CKD
    RahulChanchlani Speaker chanchlr@mcmaster.caCanadaMcMaster Children's Hospital, Hamilton, Canada
  • State-of-the-Art Treatment of Hypertension in Adults With CKD
    SusanneNicholas Speaker sunicholas@mednet.ucla.eduUnited StatesDavid Geffen School of Medicine at UCLA
  • Q and A
Hall D
4:30 p.m.
5:30 p.m.
Personalized Kidney Replacement Treatment: Adapting Guidelines to Real-world Scenarios
LF06
Annie-ClaireNadeau-Fredette Chairperson annieclairenaf@gmail.comCanadaUniversité de Montréal
Gabriel NicolasContreras Martin Chairperson gcontrer@med.miami.eduUnited StatesUniversity of Miami Miller School of Medicine
Maria ElenaBiain Chairperson mariaelenabiain@yahoo.com.arMédica Nefróloga
  • The Who, What, Where, When and Why of Incremental Hemodialysis
    ConnieRhee Speaker crhee@mednet.ucla.eduUnited StatesUCLA
  • The Changing Landscape of Home Hemodialysis: Is There a Right Patient for Home Hemodialysis?
    KarthikTennankore Speaker ktennankore@gmail.comCanadaNova Scotia Health/Dalhousie University
  • Patient-, Center- and Country-related Risk Factors for Peritoneal Dialysis Attrition: Can We Prevent It?
    RosileneM Elias Speaker rosilenemotta@hotmail.comBrazilUniversidade de Sao Paulo
  • Q and A
Hall C4

Day 3 - Tuesday April 16, 2024

Time Session
11 a.m.
12:15 p.m.
Plenary Session 4: Insights into SGLT2 Inhibitors: A Story of Discovery (Ele Ferrannini, Italy)
PL4
AlessiaFornoni Chairperson United StatesUniversity of Miami
LizLightstone Chairperson United KingdomImperial College London
MasaomiNangaku Chairperson Japan
  • Acceptance Speech: Bywaters Award
    MotokoYanagita Speaker JapanKyoto University
  • Insights into SGLT2 Inhibitors: A Story of Discovery. Donald Seldin Lecture
    EleFerrannini Speaker eleferrannini@gmail.comItalyUniversity of Pisa
  • ELP2 Graduation
    MasaomiNangaku Speaker Japan
Hall A